Interim Clinical Commissioning Policy Statement: Adalimumab for Severe Refractory Uveitis

Reference: NHS England: 170010/PS
<table>
<thead>
<tr>
<th><strong>Publications Gateway Reference:</strong></th>
<th>05527s</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Document Purpose</strong></td>
<td>Policy</td>
</tr>
<tr>
<td><strong>Document Name</strong></td>
<td>Policy Statement: Adalimumab for Severe Refractory Uveitis</td>
</tr>
<tr>
<td><strong>Author</strong></td>
<td>Specialised Commissioning Team</td>
</tr>
<tr>
<td><strong>Publication Date</strong></td>
<td>7th March 2017</td>
</tr>
<tr>
<td><strong>Target Audience</strong></td>
<td>CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs, Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Routinely Commissioned - NHS England will routinely commission this specialised treatment in accordance with the criteria described in this policy.</td>
</tr>
<tr>
<td><strong>Cross Reference</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Superseded Docs</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Action Required</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Timing / Deadlines</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Contact Details for further information</strong></td>
<td><a href="mailto:england.specialisedcommissioning@nhs.net">england.specialisedcommissioning@nhs.net</a></td>
</tr>
</tbody>
</table>

**Document Status**

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.
Interim Clinical Commissioning Policy Statement: Adalimumab for Severe Refractory Uveitis

First published: March 2017

Prepared by NHS England Specialised Services Clinical Reference Group for Specialised Ear and Ophthalmology CRG

Published by NHS England, in electronic format only.
# Contents

1. Introduction .......................................................................................................................... 7
2. Definitions ............................................................................................................................. 9
3. Aims and Objectives ............................................................................................................ 9
4. Epidemiology and Needs Assessment .............................................................................. 10
5. Evidence Base .................................................................................................................... 10
6. Criteria for Commissioning .............................................................................................. 12
7. Patient Pathway .................................................................................................................. 15
8. Governance Arrangements ............................................................................................... 15
9. Mechanism for Funding ................................................................................................. 15
10. Audit Requirements ......................................................................................................... 15
11. Documents which have informed this Policy ................................................................. 16
12. Date of Review .................................................................................................................. 16

References ............................................................................................................................. 17
Policy Statement

NHS England will commission adalimumab for severe refractory uveitis in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement

Promoting equality and addressing health inequalities are at the heart of NHS England’s values. Throughout the development of the policies and processes cited in this document, we have:

- Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities

Plain Language Summary

About Uveitis

Uveitis is an uncommon group of conditions and describes inflammation of any structure within the eye. When very severe this may lead to vision loss. Uveitis
accounts for around 10% of visual impairment registrations, which describe a spectrum of irreversible sight loss affecting both eyes to a level that precludes normal ‘print’ education or driving and includes total blindness.

Uveitis is commonly associated with a variety of inflammatory conditions affecting other organs. This policy is for the minority of cases with chronic sight threatening and visually disabling uveitis, unresponsive to previously available standard treatment.

**About current treatments**

In severe cases prevention of irreversible sight loss requires drugs that suppress immune cells (the white blood cell that protect us from infection and damage to our tissues) throughout the body. These are associated with significant short and long term side effects.

If conventional immunosuppressant treatments fail, the next step in treatment is the use of a group of drugs known as ‘biologics’. These are very specialised and are designed to target specific molecules released during inflammation from cells and by doing so suppress inflammation.

**About the new treatment**

Adalimumab is a humanised monoclonal antibody that binds to a biological mediator of inflammation called tumour necrosis factor alpha (TNF-α).

**What we have decided**

NHS England has carefully reviewed the evidence to treat uveitis with adalimumab. We have concluded that there is enough evidence to consider making the treatment available.
1 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to routinely commission Adalimumab for Adults with Severe Refractory Uveitis.

This document also describes the proposed criteria for commissioning, proposed governance arrangements and proposed funding mechanisms.

NHS England proposes this interim policy whilst pending the publication of the NICE Multiple Technology Appraisal (MTA), expected in July 2017.

https://www.nice.org.uk/guidance/indevelopment/gid-ta10007/documents

Uveitis is an eye condition which presents as inflammation (swelling) in a part of the eye called the uvea. Uveitis can affect different people in different ways depending on which part of the uvea is affected. The symptoms of uveitis may include pain, sensitivity to bright lights and poor vision. Most cases of uveitis get better with treatment. Some types of uveitis are more difficult to treat and may cause more permanent changes to vision.

Uveitis is described in different ways depending on the part of the uvea affected:

- Anterior uveitis is when the iris or ciliary body at the front of the eye is affected.
- Intermediate uveitis is when the area behind the ciliary body is affected, with most of the inflammation being seen in the vitreous, the jelly-like substance that fills the eye.
- Posterior uveitis affects the choroid (choroiditis) or retina (retinitis) or both. It can also affect the optic nerve head, where the nerve fibres leave the eye for the brain. There are many types of posterior uveitis including Birdshot chorioretinopathy or Punctate Inner Choroidopathy (PIC).
- Panuveitis is where the inflammation affects the whole uvea.
Uveitis is also described depending on how long it lasts:

- **Acute**: when your uveitis starts suddenly but improves within 3 months.
- **Recurrent**: when the inflammation flares up and settles down over months and years. Anterior uveitis is usually recurrent with acute episodes.
- **Chronic**: when the inflammation is longer lasting and also comes back within 3 months of stopping treatment. Intermediate and posterior types of uveitis are usually chronic.

Treatment for uveitis will depend on which areas of the eye are affected and what caused the condition.

First line therapy for such cases is with corticosteroids, usually in the form of prednisolone tablets. Corticosteroids have the important advantage of working quickly but have numerous side-effects especially at higher doses. For some patients, especially where only one eye is affected or where there is asymmetric bilateral disease, corticosteroids may instead be given as injections into or around the eye, an option potentially associated with complications such as cataract, glaucoma and infection.

In severe cases of uveitis, patients whose disease is not controlled on safe levels of prednisolone will require second line treatment with immunosuppressant drugs to prevent sight-loss. An ‘antiproliferative drug’ such as mycophenolate mofetil and/or a ‘calcineurin inhibitor’ such as tacrolimus may be used. These work in over 60% of patients. However, some patients remain unresponsive to treatment or suffer serious treatment side effects.

Patients unresponsive to previously available standard treatment would include those who are unable to reduce their dose of prednisolone below 10mg per day having failed to respond (due to inefficacy or intolerance) to two 2nd line agents AND have evidence of worsening visual function (assessed by visual acuity and visual field).

This interim policy proposes that for the minority of cases with chronic sight threatening and visually disabling uveitis, who are unresponsive to previously available standard treatment, treatment with adalimumab should commence.
2 Definitions

Uveitis: Uveitis is an uncommon group of conditions characterised by inflammation within the eye and describes inflammation of any structure within the eye that when very severe may cause visual loss.

Biologic drug: This term describes a range of medications which are derived from a variety of natural sources. They are not chemically synthesised and are typically manufactured using molecular biological techniques. A common example of a biologic drug is a monoclonal antibody.

Steroid refractory: Persistent inflammation despite treatment with ≥10mg oral prednisolone daily for ≥28 days.

Visual acuity: The ability to discriminate between two adjacent objects. The smaller and closer the objects are that can be discriminated from each other, the better the visual acuity. This is quantified in clinical practice using a range of scoring systems which typically require the observer to read black letters of diminishing size projected against a white background.

Visual field: This is an assessment of peripheral vision. It quantifies the limits of peripheral visual perception when an eye is looking forward.

Visual Function: The quality of a person’s vision. Central visual function is assessed by visual acuity and peripheral visual function is assessed by visual field.

3 Aims and Objectives

This policy proposition considered the interim commissioning position for the use of Adalimumab for severe refractory uveitis in adults, pending the publication of the NICE MTA appraisal currently in development (due for publication July 2017).

The objectives were to consider the evidence available and circumstances under which it would be considered appropriate and clinically effective for Adalimumab to be used in the treatment of potentially sight threatening severe refractory uveitis.
4 Epidemiology and Needs Assessment

It is estimated that in England, 220 adults per year would be eligible for treatment with adalimumab under this policy proposal. This is based on the following figures:

The prevalence of uveitis is approximately 115.3/100,000 and the incidence is approximately 52.4/100,000 (Gritz & Wong 2004).

Of all adult patients with uveitis in England we estimate 20% will have sight threatening disease requiring systemic therapy.

Of these, 60% will respond to standard immunosuppressant drugs including calcineurin inhibitors and anti-proliferative agents in combination with low-dose corticosteroids.

Of the 40% that do not respond to standard treatment, further escalation of treatment is available, prior to biologic use. This includes combining conventional 2nd line agents and using additional local therapies.

However, 10% remain unresponsive (estimated at around 220 new patients per annum in England) and will have ocular inflammation that will fulfil the eligibility criteria of this interim clinical commissioning policy for treatment with adalimumab.

5 Evidence Base

NHS England has concluded that there is sufficient evidence to support a proposal for the routine commissioning of this treatment for the indication.

Summary of new evidence

The efficacy and safety of adalimumab in the most sight-threatening forms of adult uveitis (specifically intermediate, posterior and panuveitis) has now been evaluated in two randomised controlled trials, VISUAL I and VISUAL II. Both studies were double-blind, randomised, placebo-controlled phase 3 trials in the target population of the most sight-threatening forms of adult uveitis (described anatomically as intermediate, posterior, and panuveitic disease). VISUAL I investigated the use of adalimumab in patients with active uncontrolled uveitis, whereas VISUAL II investigated the use of adalimumab in patients with clinically ‘quiescent’ disease that
was requiring high dose of maintenance corticosteroid therapy to maintain control. Both studies show significant evidence of benefit of adalimumab in terms of the primary endpoint (time to treatment failure) and that it is well tolerated with good safety profile in this population.

**VISUAL I:**

*Jaffe et al N Engl J Med 2016*

VISUAL I comprised 217 adult patients with active, non-infectious intermediate, posterior, or panuveitis despite >2 weeks of prednisolone (>10 mg/d to 60 mg/d). Active uveitis was defined as the presence of at least one of the following: active, inflammatory chorioretinal or retinal vascular lesion; anterior chamber cell grade >2+; or vitreous haze grade >2+. Patients were randomized 1:1 to adalimumab or placebo. The adalimumab group received an 80 mg baseline loading dose of adalimumab followed by 40 mg fortnightly for up to 80 weeks; all patients received prednisolone 60 mg/day that was tapered to 0 mg by week 15. The primary endpoint was time to treatment failure in at least one eye. Time to treatment failure was defined as at least one of the following: new, active, inflammatory vascular lesions; worsening of best-corrected visual acuity (BCVA) by >15 letters at or after week 6; inability to achieve >0.5+ anterior chamber (AC) cell grade or >0.5+ vitreous haze (VH) grade (at week 6); or 2-step increase in AC cell grade or VH grade (after week 6). Adverse events were monitored.

The median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group. Among the 217 patients in the intention-to-treat population, those receiving adalimumab were less likely than those in the placebo group to have treatment failure (hazard ratio, 0.50; 95% confidence interval, 0.36 to 0.70; P<0.001). Outcomes with regard to three secondary end points (change in anterior chamber cell grade, change in vitreous haze grade, and change in best corrected visual acuity) were significantly better in the adalimumab group than in the placebo group (p= 0.01 for anterior chamber cell grade; p<0.001 for vitreous haze grade; p=0.04 for visual acuity). Although no new safety signals were detected, adverse events were reported more frequently in the adalimumab group compared with the placebo group (1052.4 vs. 971.7 adverse events per 100 person-years), with injection site reactions and allergic reactions being the most common. Only six
events in the adalimumab group and three in the placebo group were directly attributed to trial intervention).

**VISUAL II:**

**Nguyen et al Lancet 2016**

VISUAL II comprised 229 patients with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by 10–35 mg/day of prednisone. Patients were randomized to receive either subcutaneous adalimumab (loading dose 80 mg; biweekly dose 40 mg) or placebo, with a mandatory prednisone taper from week 2. The primary efficacy endpoint was time to treatment failure, a multicomponent endpoint encompassing new active inflammatory chorioretinal or inflammatory retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, and visual acuity. Time to treatment failure was significantly longer in the adalimumab group compared with the placebo group (median not estimated [>18 months] vs 8.3 months; hazard ratio 0.57, 95% CI 0.39–0.84; p=0.004). The 40th percentile for time to treatment failure was 4.8 months in the placebo group and 10.2 months in the adalimumab group. The drug was well tolerated, with a similar rate of adverse events between groups and no new safety signals, showing that the drug was effective in enabling corticosteroid withdrawal in patients with inactive disease.

6 **Criteria for Commissioning**

Pending publication of the NICE MTA (expected July 2017) an interim policy has been developed for adalimumab to be used in patients who have failed to taper to 10mg prednisolone daily despite failing (due to inefficacy or intolerance) two 2nd line agents AND evidence of worsening visual function (assessed by visual acuity and visual field).

**Start Criteria**

Adults eligible for the use of adalimumab for the treatment of uveitis would meet the following criteria:
EITHER

- Failure to achieve a daily oral prednisolone dose of <10mg daily despite prior treatment with two conventional second-line immunosuppressive agents for a minimum of 3 months (eg, mycophenolate mofetil, tacrolimus, methotrexate, cyclosporine A, azathioprine) with evidence of worsening visual function.

  - Worsening visual function is defined as either a reduction in visual acuity by ≥5 logMAR letters (0.1 log units), or worsening peripheral vision (quantified by Humphrey, Goldmann or Octopus perimetry) [A logMAR (logarithm of the Minimal Angle of Resolution) chart comprises rows of letters and is used to estimate visual acuity. It is more accurate than the Snellen chart, which has traditionally been used by GPs and optometrists. It is the preferred assessment tool in research studies.]

OR

- Severe immediately sight-threatening uveitis at risk of permanent loss of vision despite treatment with ≥1.5g intravenous methyl prednisolone (in divided doses over 3 days) or 1mg/kg oral prednisolone for 1 week, defined as one or more of the following criteria:

  - Reduction of visual acuity by ≥15 logMAR letters (0.3 log units)
  - Vasculitis within the retinal vascular arcades
  - Standardization of Uveitis Nomenclature (SUN) vitreous haze score of ≥2
  - Central macular thickness >400um

Patients must be registered with NHS England’s standard electronic contractual prior approval system confirming the start criteria are met.

In Treatment

Response to therapy should be assessed after 3 months of therapy and 6 months of therapy and thereafter re-assessed every 6 months whilst treatment continues. The following data points must be collected by for each patient at these visits:
- Visual acuity measured in LogMAR
- Visual field scored as stable, worse or improved based on Humphrey, Goldmann or Octopus perimetry
- SUN anterior chamber activity and vitreous haze score
- Daily oral prednisolone dose
- Daily dose of conventional second-line immunosuppressive agents
- Frequency of topical steroid eye drops
- Intraocular pressure
- Frequency of topical antihypertensive drops
- Central macular thickness

Adults who respond to treatment with adalimumab will continue treatment for 18 months at which time a trial of treatment withdrawal will be undertaken. If relapse occurs, restarting adalimumab will be considered using the start criteria stated in this policy.

Response to treatment with adalimumab is defined as achieving one or more of the following criteria:

- Reduction in daily oral prednisolone dose by 5mg, or to ≤10mg
- Reduction in conventional second-line immunosuppressive treatment
- For eyes with impaired visual acuity, an improvement in visual acuity by ≥5 LogMAR letters (0.1 log units)
- For eyes with reduced visual field, an improvement in visual field based on an assessment using Humphrey, Goldmann or Octopus perimetry
- For eyes with increased central macular thickness, a ≥10% reduction in central macular thickness

Serious adverse events must be reported to the Medicines and Healthcare products Regulatory Agency (MHRA) using the “yellow card system” which is the official system for reporting adverse responses to medicines.
**Stop Criteria**

Adalimumab for the treatment of uveitis is stopped using following criteria:

1. Failure to achieve the response criteria defined above after 3 months of treatment
2. Adverse reaction to adalimumab

**7 Patient Pathway**

All patients fulfilling the criteria for this policy should be referred to a specialised ophthalmology service with tertiary care facilities for inflammatory ocular diseases.

**8 Governance Arrangements**

Adalimumab for the treatment of adults with severe refractory uveitis should only be initiated in tertiary specialised ophthalmology services commissioned to provide this treatment.

Prior approval will be required to ensure start criteria have been met, which will be monitored through the NHS England’s standard electronic contractual prior approval system.

**9 Mechanism for Funding**

All treatments for uveitis up to and including the use of immunosuppressant therapy are to remain funded by Clinical Commissioning Groups.

Adalimumab will be commissioned and funded by NHS England Specialised Commissioning under existing arrangements for the provision of specialised ophthalmology services.

**10 Audit Requirements**

Appropriate data fields will be included to enable collection of data through the NHS England’s standard electronic contractual prior approval system.
11 Documents which have informed this Policy

One Wales Interim Commissioning Decision. Adalimumab (Humira®) for the treatment of adult patients with severe refractory non-infectious uveitis
Date of advice: October 2016
https://openrepository.awttc.org/app/serve/resource/gbmr3178


12 Date of Review

This document will be reviewed upon publication of the NICE MTA (TA10007) expected in July 2017.
References
